Company Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases.
Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib.
The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020.
Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | Mar 29, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 164 |
| CEO | Andrew R. Robbins M.B.A. |
Contact Details
Address: 275 Wyman Street, 3rd Floor Waltham, Massachusetts 02451 United States | |
| Phone | 617-945-5576 |
| Website | cogentbio.com |
Stock Details
| Ticker Symbol | COGT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001622229 |
| CUSIP Number | 19240Q201 |
| ISIN Number | US19240Q2012 |
| Employer ID | 46-5308248 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Andrew R. Robbins M.B.A. | President, Chief Executive Officer and Director |
| Dr. John Edward Robinson Ph.D. | Chief Scientific Officer |
| Dr. Jessica Sachs M.D. | Chief Medical Officer |
| John L. Green C.A., CPA | Chief Financial Officer and Principal Accounting Officer |
| Brad Barnett | Chief Technology Officer |
| Christi Waarich | Senior Director of Investor Relations |
| Evan D. Kearns J.D. | Chief Legal Officer and Corporate Secretary |
| Erin Schellhammer | Chief People Officer |
| Dana R. Martin Pharm.D. | Senior Vice President of Medical Affairs |
| Brad Fell | Senior Vice President of Chemistry |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2024 | ARS | Filing |
| Apr 23, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 12, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 10, 2024 | EFFECT | Notice of Effectiveness |
| Apr 1, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 29, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 27, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 22, 2024 | 8-K | Current Report |
| Feb 26, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |